Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Globe Newswire (Tue, 24-Mar 8:00 AM ET)
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 16-Mar 4:05 PM ET)
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 12-Mar 4:05 PM ET)
What To expect before MLYS earnings announcement?
Market Chameleon (Tue, 10-Mar 7:41 AM ET)
Market Chameleon (Tue, 10-Mar 7:25 AM ET)
Globe Newswire (Mon, 9-Mar 4:30 PM ET)
History Shows MLYS could rally into earnings
Market Chameleon (Mon, 9-Mar 8:22 AM ET)
Globe Newswire (Mon, 9-Mar 8:00 AM ET)
PRNewswire (Tue, 3-Mar 5:31 PM ET)
Globe Newswire (Tue, 6-Jan 8:00 AM ET)
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Mineralys Therapeutics trades on the NASDAQ stock market under the symbol MLYS.
As of April 1, 2026, MLYS stock price declined to $26.56 with 671,120 million shares trading.
MLYS has a beta of 1.31, meaning it tends to be more sensitive to market movements. MLYS has a correlation of 0.06 to the broad based SPY ETF.
MLYS has a market cap of $2.19 billion. This is considered a Mid Cap stock.
In the last 3 years, MLYS traded as high as $47.65 and as low as $5.85.
The top ETF exchange traded funds that MLYS belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
MLYS has outperformed the market in the last year with a price return of +67.3% while the SPY ETF gained +18.5%. However, in the short term, MLYS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -26.8% vs -3.6% return in SPY. But in the last 2 weeks, MLYS shares have fared better than the market returning +6.2% compared to SPY -2.0%.
MLYS support price is $25.82 and resistance is $28.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLYS shares will trade within this expected range on the day.
